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Abstract 
Background: Isepamicin is a weakly toxic but highly active aminoglycoside antibiotic derivative of gentamicin B. 
Gentamicin B is a naturally occurring minor component isolated from Micromonospora echinospora. 2ʹ-NH2-containing 
gentamicin C complex is a dominant compound produced by wild-type M. echinospora; by contrast, 2ʹ-OH-
containing gentamicin B is produced as a minor component. However, the biosynthetic pathway of gentamicin B 
remains unclear. Considering that gentamicin B shares a unique C2ʹ hydroxyl group with kanamycin A, we aimed to 
design a new biosynthetic pathway of gentamicin B by combining twelve steps of gentamicin biosynthesis and two 
steps of kanamycin biosynthesis.
Results: We blocked the biosynthetic pathway of byproducts and generated a strain overproducing JI-20A, which 
was used as a precursor of gentamicin B biosynthesis, by disrupting genK and genP. The amount of JI-20A produced in 
M. echinospora ∆K∆P reached 911 μg/ml, which was 14-fold higher than that of M. echinospora ∆P. The enzymes KanJ 
and KanK necessary to convert 2ʹ-NH2 into 2ʹ-OH from the kanamycin biosynthetic pathway were heterologously 
expressed in M. echinospora ΔKΔP to transform JI-20A into gentamicin B. The strain with kanJK under PermE* could 
produce 80 μg/ml of gentamicin B, which was tenfold higher than that of the wild-type strain. To enhance gentamicin 
B production, we employed different promoters and gene integration combinations. When a PhrdB promoter was 
used and kanJ and kanK were integrated in the genome through gene replacement, gentamicin B was generated as 
the major product with a maximum yield of 880 μg/ml.
Conclusion: We constructed a new biosynthetic pathway of high-level gentamicin B production; in this path-
way, most byproducts were removed. This method also provided novel insights into the biosynthesis of secondary 
metabolites via the combinatorial biosynthesis.
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Background
Aminoglycoside antibiotics have been widely used to 
treat severe bacterial infections; for instance, strepto-
mycin was administered as the first effective anti-tuber-
culosis agent. Other aminoglycoside antibiotics include 
2-deoxystreptamine (2-DOS) containing gentamicin, 
kanamycin, neomycin, and butirosin. However, the 
critical resistance mechanism of aminoglycoside anti-
biotics in pathogens is enzymatic inactivation. As such, 
semi-synthetic aminoglycosides have been created to 
overcome pathogen enzymatic inactivation. For exam-
ple, isepamicin is developed by introducing (S)-3-amino-
2-hydroxypropionyl side chains to the 1-amino group of 
gentamicin B. This side chain can block the modification 
by various aminoglycoside-modifying enzymes. Thus, 
isepamicin is highly stable against aminoglycoside-inac-
tivating enzymes [1].
Isepamicin is manufactured from gentamicin B, which 
is co-produced in Micromonospora echinospora. Gen-
tamicin C complex is produced by M. echinospora as its 
major product. By contrast, gentamicin A, B, and X are 
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yielded by M. echinospora as minor components [2]. 
Gentamicin A and X are intermediates of gentamicin C 
biosynthesis. However, gentamicin B is not an interme-
diate of the gentamicin C biosynthetic pathway because 
gentamicin B cannot be biotransformed by M. echinos-
pora into any gentamicin C component [2]. Thus far, the 
biosynthetic pathway of gentamicin B remains unclear.
The biosynthetic pathway of gentamicin has been 
elucidated (Fig.  1). The gene cluster of gentamicin has 
also been cloned [3, 4]. The genes involved in the bio-
synthesis of pseudodisaccharide paromamine and pseu-
dotrisaccharide gentamicin A2 have been identified 
[5]. The production of gentamicin X2 from A2 involves 
four enzymes: oxidoreductase, transaminase, and two 
methyltransferases [6]. X2 can also be transformed into 
JI-20A by C-6ʹ dehydrogenase and transaminase [7–9]. 
Moreover, GenK is the methyltransferase of C-6ʹ in gen-
tamicin, and genK disruption generates a gentamicin 
C1a-overproducing strain [10–12]. GenP is a phospho-
transferase participating in 3ʹ,4ʹ-deoxygenation in the 
gentamicin biosynthetic pathway [13]. If genP is dis-
rupted, JI-20A,JI-20B, and JI-20Ba accumulate in mutant 
strains [9]. In this study, genK and genP were disrupted 
simultaneously to generate strains producing JI-20A, 
which was designed as a precursor of gentamicin B bio-
synthesis (Fig. 1).
The structure of gentamicin B resembles that of both 
gentamicin C and kanamycin A. Unlike most 2-DOS-
containing aminoglycosides, kanamycin A contains a 
hydroxy group at C2ʹ; gentamicin B shares this unique 
structure with kanamycin A. The methylated pentose 
ring of gentamicin B is also similar to that of gentamicin 
C and is designated as garaosamine. Gentamicin B can 
be synthesized via a biosynthetic pathway similar to that 
of kanamycin A on the basis of molecular structure. In 
the kanamycin A biosynthetic pathway in Streptomyces 
kanamyceticus, 2ʹ-NH2 is converted into 2ʹ-OH by using 
KanJ and KanK; in the process, 2-oxoglutarate, Fe2+, O2, 
and NADH are utilized [14]. We hypothesized that gen-
tamicin B could be biosynthesized from JI-20A, a com-
pound structurally similar to gentamicin B, except NH2 
group at C2ʹ (Fig.  1). Thus, JI-20A could be converted 
into gentamicin B in JI-20A-overproducing strain via two 
steps catalyzed by KanJ and KanK. Using the assembly 
and metabolically engineered biosynthesis pathway of 
gentamicin B, we can eliminate byproducts and improve 
gentamicin B production.
Results and discussion
Construction of JI‑20A‑overproducing strain by disrupting 
genP and genK genes
The original strain can potentially generate gentamicin 
B; as such, we determined whether gentamicin B is 
synthesized from the 2ʹ-amino-containing precursor 
by the KanJ and KanK homologs. However, the genes 
homologous to kanJ and kanK have yet to be detected in 
M. echinospora. Considering that the biosynthetic path-
way of gentamicin B remains unclear, we aimed to con-
struct an artificial pathway of gentamicin B biosynthesis. 
JI-20A and gentamicin B are similar in terms of chemical 
structure except at C2ʹ. JI-20A contains an amino group 
at C2ʹ, whereas gentamicin B comprises a hydroxyl group 
at the same position. The structural difference between 
JI-20A and gentamicin B is similar to the difference 
between kanamycin A and B. Considering that kanamy-
cin B is converted into kanamycin A by KanJ and KanK, 
we determined whether KanJ and KanK can also trans-
form JI-20A into gentamicin B.
To generate a JI-20A-producing strain, we simultane-
ously disrupted the 6ʹ-methyltransferase gene genK and 
the 3ʹ-phosphotransferase gene genP in this study (Fig. 2). 
We separately generated genP- and genK-disrupting 
strains in our previous work [6, 7]. The genP-disrupting 
strain does not produce gentamicin C complex, which 
are the main products of the wild-type strain but are the 
main byproducts in gentamicin B production. In this 
study, the genK-disrupting plasmid was introduced to 
M. echinospora ∆P to obtain the double-gene-disrupting 
strain M. echinospora ∆K∆P (Additional file  1: Figure 
S1A). The disrupting strain was fermented and its prod-
ucts were analyzed through high-performance liquid 
chromatography with evaporative light scattering detec-
tor (HPLC-ELSD). JI-20B and JI-20Ba were the main 
products of M. echinospora ∆P but were undetectable in 
M. echinospora ∆K∆P (Fig.  3). JI-20A was produced up 
to 911  μg/ml, which was 14-fold higher than that pro-
duced by M. echinospora ∆P. We blocked the biosynthesis 
of gentamicin C1, C1a, C2, C2a, JI-20B, and JI-20Ba and 
generated a JI-20A-overproducing strain by disrupting 
genP and genK.
Construction of a new gentamicin B biosynthetic pathway 
through the heterologous expression of kanJ and kanK
The kanJ and kanK genes under the control of the strong 
promoter PermE* were cloned into the site-specific inte-
gration plasmid pEAP1 to construct pSPUJK1. pSPUJK1 
was introduced to M. echinospora ∆K∆P through con-
jugation and exconjugants were selected through eryth-
romycin resistance; as a result, M. echinospora JK1 was 
generated (Additional file 1: Figure S1B). M. echinospora 
JK1 was fermented under the same condition used to fer-
ment the wild-type strain. The fermentation products of 
M. echinospora JK1 were also analyzed through HPLC-
ELSD. Compared with the wild-type strain, M. echinos-
pora JK1 produced a new product exhibiting a retention 
time similar to that of gentamicin B (Fig. 3).
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To determine the structure of the new product of 
M. echinospora JK1, we analyzed the purified prod-
uct through mass spectrometry. The exact mass of the 
product was 482.26 (m/z 483.26), which corresponds 
to gentamicin B (Fig.  4). Furthermore, the protonated 
fragments were the same as those of the reported mass 
spectra of gentamicin B [15], that is, the glycoside bond 
of gentamicin B cleavage formed the fragment b  +  c 
(m/z 324.17). The glycoside found at the C6–O of 2-DOS 
decomposed; thus, the fragments b + c + x (m/z 366.18) 
were produced. Nevertheless, gentamicin B yields the 
same molecular weight as that of gentamicin X2, which 
is another minor component of gentamicin. To verify 
the structure of the new product, we recorded the cor-
responding 1H and 13C NMR data. The 1H spectrum of 
the new product was similar to that of gentamicin B [16] 
(Additional file  2: Figure S2). Moreover, the 13C NMR 
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Fig. 1 Biosynthetic pathway for gentamicin and the proposed strategy for gentamicin B biosynthetic pathway (inside the dashed line)
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reported NMR data of gentamicin B [17]. MS and NMR 
data demonstrated that the product from M. echinospora 
JK1 is gentamicin B.
Although gentamicin B production is greatly improved 
in M. echinospora JK1 compared with that of the wild-
type strain, the yield is only 85 μg/ml in M. echinospora 
JK1. A large quantity of JI-20A in M. echinospora JK1 
was also found in the fermentation broth. Therefore, 
the expression levels of kanJ and kanK were genetically 
manipulated to improve gentamicin B production.
Enhancing gentamicin B production through the genetic 
manipulation of kanJK
The genetic stability of the strains applied in industrial 
fermentation is very important. However, gentamicin 
B production in M. echinospora JK1 decreased from 
162 μg/ml to 80 μg/ml in five generations of unselected 
passages (Fig. 5a). We proposed that the instability of M. 
echinospora JK1 is caused by the homologous recombi-
nation between the PermE* upstream of kanJK and the 
native promoter of ermE, which was used as a selection 
marker gene in pSPUJK1. In addition, the instability may 
be caused by chromosomal rearrangements or plasmid 
elimination from the chromosome, which can occur 
when a φC31-derived plasmid is used in strains contain-
ing multiple pseudo attB sites [18].
To avoid genetic instability, we integrated kanJ and 
kanK into the chromosome through homologous recom-
bination instead of site-specific insertion. Considering 
that genP has been disrupted in M. echinospora ∆K∆P, 
we designed kanJ and kanK to replace genP (Additional 
file  1: Figure S1C). To reduce JI-20A production and 
improve gentamicin B production, we placed kanJ and 
kanK under the control of the strong promoter PermE* 
(Fig.  2). Moreover, the fermentation broth of the gene 
replacement strain M. echinospora JK2 was analyzed 
through HPLC-ELSD. Figure  5a shows that the gen-
tamicin B production by M. echinospora JK2 was more 
stable than that by M. echinospora JK1. Gentamicin B 
production increased to 342 μg/ml. However, M. echinos-
pora JK2 produced a considerable quantity of JI-20A.
The native promoter of genP was used to improve 
gentamicin B production. To eliminate any possibility 
of polar effects on other genes, we designed kanJK as a 
replacement of the open reading frame of genP, and no 
other elements were introduced (Additional file 1: Figure 
S1D). As such, the native ribosome binding site (RBS) 
and promoter of genP (or promoter of its operon) were 
employed by kanJK. Although the regulatory elements 
of genP have yet to be determined, we proposed that all 
regulatory elements of genP can be used. In the fermenta-
tion of M. echinospora JK3, kanJK was expressed as gen-
tamicin B was produced in JK3. Gentamicin B production 
also reached 436 μg/ml. PermE*, which exhibits a strong 
promoter activity, is widely used for the gene expression 
in Actinomyces. However, this work found that PermE* 
is weaker than the native promoter of genP.This phe-
nomenon occurred possibly because PermE* originates 
from Saccharopolyspora erythraea; as such, PermE* can-
not be as effective in M. echinospora as in S. erythraea. 
Another possible cause is the ineffectiveness of the RBS 
of the construction because the translation initiation of 
PermE*-kanJ-kanK is weak when analyzed with the RBS 
Calculator [19].
Fig. 2 Genotypes of M. echinospora and its recombinant strains
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JI-20A accumulation in the fermentation broths of M. 
echinospora JK2 and JK3 indicated the inefficiency of 
KanJ and KanK. Thus, an increase in KanJK expression 
may enhance their total activity and gentamicin B pro-
duction. The PhrdB promoter of Streptomyces coelicoloris 
stronger than PermE* [20]. Therefore, a kanJK under the 
control of PhrdB was constructed and introduced to M. 
echinospora ∆K∆P; as a result, a mutant strain M. echi-
nospora JK4 was generated (Additional file 1: Figure S1E).
The HPLC analysis of the fermentation broth of M. 
echinospora JK4 revealed that gentamicin B produc-
tion reached 880  μg/ml; by contrast, JI-20A production 
decreased to 143 μg/ml. Figure 5b shows that gentamicin 
B production increased by 2.5-fold when the PhrdB pro-
moter was used compared with that when PermE* was 
used. This result confirmed that the expression level of 
KanJK was enhanced by replacing the promoter PermE* 
with PhrdB.
The genome analysis of Actinomyces revealed the 
presence of numerous gene clusters encoding second-
ary metabolites [21]. Actinomyces can be metabolically 
engineered to overproduce native metabolites or ana-
logs. With the development of synthetic biological tools, 
improved bioinformatics tools of metabolic engineering, 
and enhanced sensitivity and sophistication of analytical 
methods, secondary metabolite production is feasible in 
various cellular factories [22].
Conclusions
We successfully established an artificial biosynthetic 
pathway to achieve a high-level production of gentamicin 
B. The genes genK and genP were disrupted in M. echi-
nospora to producethe JI-20A, which is the precursor of 
gentamicin B. JI-20Aproduction in the gene-disrupting 
strain M. echinospora ΔKΔP reached 911  μg/ml, which 
was 14-fold higher than that of M. echinospora ∆P. We 
disrupted the biosynthesis of gentamicin C1, C1a, C2, 
C2a, JI-20B, and JI-20Ba by disrupting genP and genK. 
The removal of byproducts in fermentation broth will be 
beneficial to purification because antibiotic purification 
is costly and time consuming.
An artificial pathway for the conversion of JI-20A to 
gentamicin B was constructed through the heterolo-
gous overexpression of kanJ and kanK in M. echinospora 
ΔKΔP. The kanJK-overexpressing strain under the control 
of PermE* can produce 80  μg/ml gentamicin B, which 
was tenfold higher than that of the wild-type strain. Dif-
ferent promoters and gene integration combinations 
were investigated to improve gentamicin B production. 
When the PhrdB promoter was used and kanJ and kanK 
were integrated in the genome through gene replace-
ment, gentamicin B was produced as a major product 
with a maximum yield of 880  μg/ml.These results con-
firmed that microbiological strains can be engineered 
through the metabolic engineering of an intrinsic biosyn-
thetic pathway and the introduction of exogenous genes 
to produce high yields of target products.
Methods
Bacterial strains, plasmids, media, and culture conditions
The strains and plasmids used in this work are listed in 
Table  2. Escherichia coli Top10 was used as the clon-
ing host grown on Luria–Bertani (LB) liquid or solid 
medium. Liquid ATCC172 was used for the vegetative 
growth of M. echinospora. The conjugal transfer was 
Fig. 3 HPLC-ELSD analysis of gentamicin production in fermenta-
tions. gB gentamicin B, 20Ba JI-20Ba
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performed on MS agar. Solid slanting medium was used 
for M. echinospora sporulation. The previously described 
media and culture conditions were used for gentamicin 
production [8].
Construction of kanJ and kanK expression plasmids
DNA isolation and manipulation were performed as 
described by Sambrook [23]. Additional file  3: Table S1 
lists the primers used in this work. The kanJ and kanK 
genes were amplified from the genomic DNA of S. kana-
myceticus. The primers were designed using the biosyn-
thetic gene sequence of kanamycin (GenBank accession 
number: AJ628422.2) and gentamicin (GenBank acces-
sion number:AJ628149.4). The primers Pkanjk-up1 and 
Pkanjk-down1 were used to amplify a 1.95  kb fragment 
containing intact kanJ and kanK. The PCR product was 
digested with HindIII and BamHI and then ligated to 
pSPU241; thus, pJK241 was generated. The 2.6 kb insert 
containing PermE*-kanJK-To was recovered as a BglII 
fragment and then inserted into the same site of pEAP1 
to generate pSPUJK1.
The primers Ph1 and Ph2 were used to amplify the 
downstream homologous arm and to generate a gene 
replacement vector with kanJK genes under PermE*. 
The primers Ph3 and Ph4 were utilized to amplify the 
Fig. 4 Structural determination of gentamicin B by MS/MS. a Structure of gentamicin B. b Mass spectra of the new product from M. echinosporaJK1
Table 1 13C NMR spectral data for  gentamicin B [16] 
and the new compound from M. echinospora JK1 (for atom 
numbering see Fig. 1)
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upstream homologous arm. Pkanjk-up2 and Pkanjk-
down2 were also employed to amplify the intact kanJK 
fragment. Perm-up and Perm-down were used to 
amplify PermE*. PermE*, kanJK, and the upstream 
homologous arm fragment were fused through over-
lap extension PCR in accordance with a previously 
described procedure [24]. The overlapping PCR product 
was ligated with pMD18-T (Takara) and digested with 
XbaI and SmaI; the downstream homologous arm was 
digested with XbaI and SmaI. Afterward, the digested 
fragments were ligated to pKC1139; thus, pSPUJK2 was 
generated.
The primers Ph1 and Ph2 were used to amplify the 
downstream homologous arm and the primers Ph33 and 
Ph4 were utilized to amplify the upstream homologous 
arm to generate a vector for gene replacement. Pkanjk-
up3 and Pkanjk-down2 were also used to amplify kanJK. 
The overlap extension PCR was employed using the 
primers Ph4 and Pkanjk-down2 to fuse the kanJK frag-
ment and the upstream homologous arm. The overlap 
PCR product was ligated using pMD18-T(Takara) and 
then digested with XbaI and SmaI. The downstream 
homologous arm was digested with XbaI and SmaI. The 
digested fragments were then ligated to pKC1139; thus, 
pSPUJK3 was generated.
The primers Ph34 and Ph4 were used to amplify the 
upstream homologous arm to generate a gene replace-
ment vector with kanJK genes under the strong promoter 
PhrdB. Pkanjk-up4 and Pkanjk-down2 were utilized to 
amplify the intact kanJK fragment. Phrd-up and Phrd-
down were also used to amplify PhrdB. The upstream 
homologous arm fragment, PhrdB, and kanJK were 
then fused through overlap extension PCR. The overlap 
PCR product was then ligated with pMD18-T and then 
digested with XbaI and SmaI. The downstream homolo-
gous arm was digested with XbaI and SmaI. The digested 
fragments were ligated to pKC1139. Thus, pSPUJK4 was 
generated.
Construction of genK‑disrupting and kanJK‑expressing 
strains
genK-disrupting and kanJK-expressing plasmids were 
introduced to M. echinospora through conjugation on 
MS medium at 28  °C for 24 h. After the medium was 
Fig. 5 Production and stability analysis of gentamicin B-producing strains. a Stability of gentamicin B production in M. echinosporaJK1 and JK2 
strains. b Production analysis of gentamicin B in M. echinospora ΔKΔP and kanJK heterologous expression strains. Error bars represent standard 
deviations. Samples were analyzed through HPLC and quantified on the basis of the peak areas
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spread with 50  mg of apramycin (erythromycin was 
used for pSPUJK1) and 100 mg of pipemidic acid per 
liter, incubation was performed at 28  °C for 7  days. 
Exconjugants were initially selected to determine the 
apramycin-resistance (the first crossover event) phe-
notype because pSPU503, pSPUJK2, pSPUJK3, and 
pSPUJK4 plasmids contain an apramycin-resistance 
gene; the apramycin-sensitive (the second crossover 
event) phenotype was then used to isolate the strains 
via the desired double-crossover homologous recom-
bination event. Genomic DNA was extracted and used 
as a template DNA in PCR. The PCR products were 
subjected to DNA sequencing to demonstrate that 
kanJ and kanK exist in the kanJK-expressing strains.
Antibiotic isolation and analysis
The pH of the culture broth was adjusted to 2.0 by 
using H2SO4. The acidified broth was agitated for 
30  min and then centrifuged at 11,378×g 10  min. 
The pH of the supernatant was readjusted to 7.0 with 
NaOH. The pretreated supernatant was centrifuged 
again at 11,378×g for 10  min. The supernatant was 
then applied to strongly acidic resin 001  ×  7 (Shan-
dong Lukang Record Pharmaceutical Co., Ltd).The 
bound substances were eluted with 2  mol/L NH4OH. 
Second cation-exchange chromatography was per-
formed on weakly acidic resin D152 (Shandong 
Lukang Record Pharmaceutical Co., Ltd). The bound 
substances were eluted with the gradient elution of 
NH4OH (from 0.1 to 1.0 mol/L).
The elution from the acidic resin was used as the 
sample for the reversed-phase HPLC-ELSD analysis in 
a reverse C18 column at an evaporation temperature 
of 45  °C, nitrogen pressure of 3.5  bar, and a mobile 
phase of 0.2  mol/L trifluoroacetatic acid–methanol 
(97:3) at a flow rate of 0.6  ml/min. Authentic gen-
tamicin B was used as standard. The purified prod-
ucts were analyzed using an LC/MS/MS instrument 
(Bruker micrOTOF-Q). The mass spectrometer was 
set in a positive mode. 1H and 13C NMR data were 
recorded on Bruker AV600 at 600  MHz frequency, 
and D2O was used as a solvent.
Table 2 Strains and plasmids used in this study
AmpR ampicillin resistance, AmR ampramycin resistance, ErmR erythromycin resistance
Strains or plasmids Relevant characteristic Reference or source
Strains
 E. coli TOP10 F-mcrAΔ(mrr-hsdRMS-mcrBC), φ80lacZΔM15,ΔlacX74, deoR, recA1, araD139Δ(ara-leu)7697, galU, galK, 
rpsL(StrR), endA1, nupG
Invitrogen
 E. coli ET12567/ 
pUZ8002
Methylation defective, strain used in E. coli-streptomyces intergeneric conjugation [25]
 S. kanamyceticus Kanamycin producing strain CGMCC4.1441
 M. echinospora Wild-type strain, gentamicin C1a, C2, C2a, and C1 producer ATCC 15835
 M. echinosporaΔP M. echinospora with disrupted genP [7]
 M. echinosporaΔKΔP M. echinospora with disrupted genK and genP This study
 M. echinospora JK1 Heterologous, genome-based expression of kanJ and kanK, with replacement of the native promoter 
by PermE* in M. echinosporaΔKΔP.
This study
 M. echinospora JK2 M. echinosporaΔKΔP + heterologous expression of kanJ and kanK under the promoter PermE*, inser-
tion at genP locus in M. echinospora ΔKΔP
This study
 M. echinospora JK3 Heterologous expression of kanJ and kanK under promoter PgenP, insertion at genP locus in M. echinos-
pora ΔKΔP
This study




 pKC1139 E. coli-streptomyces shuttle vector, AmR [26]
 pSPU241 pIJ2925 derivative carrying the Streptomyces constitutive promoter PermE* and To terminator, AmpR [8]
 pEAP1 pSET152 carrying ermE, the apramycin resistance-conferring gene aac(3)IV was replaced by the ampi-
cillin resistance-conferring gene bla, AmpR, ErmR
[8]
 pSPU503 pKC1139 carrying homologous arms of genK (gacD), used in genK disruption [12]
 pJK1 pEAP1 carrying PermE*-kanJ-kanK, used in generating M. echinospora JK1 This study
 pJK2 pKC1139 carrying homologous arms and kanJK, used in generating M. echinospora JK2 This study
 pJK3 pKC1139 carrying homologous arms and PermE*-kanJ-kanK, used in generating M. echinospora JK3 This study
 pJK4 pKC1139 carrying homologous arms andPhrdB-kanJ-kanK, used in generating M. echinospora JK4 This study
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